AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback